MILESTONE PHARMACEUTICLS ($MIST) posted quarterly earnings results for Q1 2026 on Wednesday, May 13th. The company reported earnings of -$0.20 per share, missing estimates of $0.31 by $0.51. The company also reported revenue of $240,000, missing estimates of $38,397,900 by $-38,157,900.
You can see Quiver Quantitative's $MIST stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MILESTONE PHARMACEUTICLS Insider Trading Activity
MILESTONE PHARMACEUTICLS insiders have traded $MIST stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $MIST stock by insiders over the last 6 months:
- JOSEPH OLIVETO (President and CEO) has made 0 purchases and 5 sales selling 247,577 shares for an estimated $555,679.
- AMIT HASIJA (CFO & EVP of Corp. Development) has made 0 purchases and 2 sales selling 70,252 shares for an estimated $158,209.
- DAVID BHARUCHA (Chief Medical Officer) has made 0 purchases and 2 sales selling 70,252 shares for an estimated $158,209.
- JEFFREY EDWARD NELSON (Chief Operating Officer) has made 0 purchases and 2 sales selling 70,252 shares for an estimated $158,209.
- LORENZ MULLER (Chief Commercial Officer) has made 0 purchases and 2 sales selling 64,746 shares for an estimated $145,850.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
MILESTONE PHARMACEUTICLS Hedge Fund Activity
We have seen 48 institutional investors add shares of MILESTONE PHARMACEUTICLS stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ORBIMED ADVISORS LLC removed 3,221,828 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $6,508,092
- MORGAN STANLEY removed 2,187,192 shares (-73.7%) from their portfolio in Q4 2025, for an estimated $4,418,127
- MARSHALL WACE, LLP added 1,231,793 shares (+289.8%) to their portfolio in Q4 2025, for an estimated $2,488,221
- PROPEL BIO MANAGEMENT, LLC removed 1,006,569 shares (-19.6%) from their portfolio in Q4 2025, for an estimated $2,033,269
- TWO SIGMA INVESTMENTS, LP added 847,910 shares (+127.2%) to their portfolio in Q4 2025, for an estimated $1,712,778
- SPHERA FUNDS MANAGEMENT LTD. removed 820,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,656,400
- JANE STREET GROUP, LLC added 684,738 shares (+167.6%) to their portfolio in Q4 2025, for an estimated $1,383,170
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
MILESTONE PHARMACEUTICLS Analyst Ratings
Wall Street analysts have issued reports on $MIST in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/06/2026
- Wells Fargo issued a "Overweight" rating on 12/16/2025
To track analyst ratings and price targets for MILESTONE PHARMACEUTICLS, check out Quiver Quantitative's $MIST forecast page.
MILESTONE PHARMACEUTICLS Price Targets
Multiple analysts have issued price targets for $MIST recently. We have seen 3 analysts offer price targets for $MIST in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Brandon Folkes from HC Wainwright & Co. set a target price of $8.0 on 01/06/2026
- Mohit Bansal from Wells Fargo set a target price of $8.0 on 12/16/2025
- Ritu Baral from TD Cowen set a target price of $8.0 on 12/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
